GIA® vs. Linus Health
Cognitive assessment is one domain. Clinical screening across 46 conditions is a different category entirely.
Linus Health is a digital cognitive assessment platform that acquired Winterlight Labs, a speech analysis research company focused on cognitive impairment detection. Linus Health offers tablet-based cognitive assessments that digitize traditional tools like the Clock Drawing Test. Their platform focuses on cognitive health, primarily Alzheimer’s and related dementias. GIA® by Scienza Health screens for 46 conditions across cognitive, behavioral, and neurological health in a single autonomous conversation lasting under 5 minutes. Where Linus Health digitizes cognitive testing, GIA® conducts multimodal clinical screening using Voice AI, Computer Vision, and 2,500+ Speech Biomarkers simultaneously, with results prepared for clinician review and submission to the EHR.
How do they compare?
| Dimension | Linus Health | GIA™ |
|---|---|---|
| Conditions screened | Cognitive health (Alzheimer’s and related dementias) | 46 conditions: cognitive, behavioral, neurological |
| Screening modality | Tablet-based cognitive tasks and speech analysis | Multimodal: Voice AI, Computer Vision, Speech Biomarkers |
| Staff requirement | Clinician administration or supervision (based on available information) | Zero during screening. Clinician reviews results. |
| Screening time | Varies by assessment module | Under 5 minutes for all 46 conditions |
| Autonomy | Requires supervised patient interaction | Fully autonomous Digital Human® |
| 510(k) clearance | Check vendor documentation | 510(k) cleared |
| EHR integration | Check vendor documentation | Results, notes, transcript, video prepared for clinician review |
| Training dataset | Not publicly disclosed at comparable scale | 12.3M patients, 27B clinical records |
| Device deployment | Tablet-based | Samsung Health Grade Galaxy devices, iOS, web, landline |
Where linus health falls short
A digital cognitive assessment platform offering tablet-based cognitive testing, including digitized versions of traditional tools like the Clock Drawing Test. Acquired Winterlight Labs for speech-based cognitive analysis.
- Focused on cognitive assessment only. Does not screen for depression, anxiety, PTSD, Parkinson’s, substance abuse, or other behavioral and neurological conditions
- Based on available information, assessments require clinician administration or supervised patient interaction with a tablet
- Cognitive assessment focus. GIA® by Scienza Health screens across cognitive, behavioral, and neurological categories
- Primarily targets Alzheimer’s and related dementias. Does not address the broader spectrum of conditions seen in post-acute and long-term care
- Based on available information, does not offer autonomous screening. A staff member is typically involved in the assessment process
- Assessment results may require manual EHR documentation
- Speech analysis capability inherited from Winterlight Labs acquisition focuses on cognitive markers, not the full range of speech biomarkers tied to behavioral and neurological health
- No published multimodal analysis combining voice, computer vision, and speech biomarkers in a single session
What GIA™ does differently
- Screens for 46 conditions across cognitive, behavioral, and neurological health in a single conversation
- Fully autonomous. GIA® conducts the entire screening interaction. Zero clinical staff required during the session
- Multimodal: Voice AI, Computer Vision, and 2,500+ Speech Biomarkers analyzed simultaneously
- 510(k) cleared for clinical screening
- Four data types are prepared for clinician review and submission to the EHR: screening results, medical notes, transcript, patient video
- Powered by 12.3M patients and 27B clinical records
- Pre-bundled on Samsung Health Grade Galaxy devices with Samsung Knox security
- GIA® speaks 92 languages for patient comfort and rapport
Linus Health digitizes cognitive assessment. GIA® conducts autonomous multimodal screening across 46 conditions. If a facility’s only need is cognitive testing, Linus Health is a focused tool for that domain. If the need is comprehensive clinical screening that covers cognitive, behavioral, and neurological health in a single patient conversation with no staff time, GIA® operates in a different category. One is a digital test. The other is a clinical screening platform.
Common questions
Does GIA® screen for the same cognitive conditions as Linus Health?
Yes. GIA® screens for Alzheimer’s disease, Mild Cognitive Impairment, cognitive decline, and Huntington’s disease, among other neurodegenerative conditions. GIA® also screens for 46 total conditions including depression, anxiety, PTSD, Parkinson’s, and substance abuse, which fall outside Linus Health’s cognitive focus.
Does Linus Health use speech biomarkers?
Linus Health acquired Winterlight Labs, which developed speech analysis technology focused on cognitive impairment markers. GIA® analyzes 2,500+ speech biomarkers across cognitive, behavioral, and neurological conditions, combined with Computer Vision and Voice AI in a single multimodal session.
Does GIA® require a clinician during the screening?
No. GIA® is a registered Digital Human® that conducts the entire screening conversation autonomously. The clinician reviews results after the session, which takes under 2 minutes. Based on available information, Linus Health assessments typically involve clinician administration or supervised patient interaction.
Which platform has 510(k) clearance?
GIA® by Scienza Health is 510(k) cleared for multimodal clinical screening across 46 cognitive, behavioral, and neurological conditions. 510(k) clearance means the FDA has reviewed the platform for substantial equivalence, providing regulatory confidence for clinical deployment.
Can GIA® replace Linus Health in a facility?
GIA® covers cognitive screening and extends to 46 conditions across behavioral and neurological health. Facilities currently using Linus Health for cognitive assessment would gain broader screening coverage, autonomous operation, multimodal biomarker analysis, and real-time EHR write-back by adopting GIA®.
How does the training data compare?
GIA® by Scienza Health is powered by 12.3M patients and 27B clinical records. Peer-reviewed validation from Beth Israel Deaconess Medical Center, NIH, and MIT. 19 peer-reviewed studies support the platform.
The Operator's Guide to Multimodal Clinical AI
What administrators, DONs, and regional operators need to know before evaluating clinical AI platforms. Covers EHR integration, staffing impact, reimbursement codes, and deployment timelines.